公司概述
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical entity within the United States market, focusing its product development on PEDMARK, a specific formulation of sodium thiosulfate designed to prevent cisplatin-induced ototoxicity in pediatric patients. The company functions within the broader Healthcare sector and specifically the Biotechnology industry, positioning itself to address critical therapeutic needs in pediatric oncology care while leveraging a specialized commercialization strategy. In terms of scale, Fennec Pharmaceuticals holds a market capitalization of $220.64 million and generates total annual revenue of $44.64 million based on trailing twelve-month data, supported by an operational workforce of 35 employees. These valuation and revenue figures indicate that the company maintains a significant market presence for a biotechnology firm of its size, with a market cap that exceeds its current revenue multiple, reflecting the high valuation typically associated with biotech assets in the development or early commercialization phases. The disparity between the substantial market capitalization and the relatively modest revenue stream highlights the market's expectation of future growth derived from the commercialization of its key product candidate rather than current earnings performance.
财务健康
The company reported a revenue of $44.64 million for the trailing twelve months, while the net income stood at a loss of $9,741,000, and the EBITDA was recorded at a negative $6,179,333. The significant gap between the positive revenue of $44.64 million and the negative net income of $9,741,000 reveals a cost structure where operating expenses, likely driven by research and development or commercialization costs, substantially exceed the gross profit generated from sales. Free cash flow for the period was negative at $7,332,250, indicating that the company is currently burning cash to fund its operations and growth initiatives rather than generating surplus liquidity for distribution or debt repayment. Despite the negative cash flow, the balance sheet retains a robust cash position of $36.79 million, which provides a critical buffer to sustain operations without immediate external capital raising. The company carries zero debt, resulting in a debt-to-equity ratio that is effectively N/A due to the absence of liabilities, which signifies a highly conservative balance sheet free from leverage risks. Furthermore, the current ratio is calculated at 6.37, a figure that indicates exceptional short-term liquidity and an overwhelming ability to cover current liabilities with its liquid assets. Return on Equity is reported at -65.8% and Return on Assets at -6.8%, metrics that reveal that management is currently generating negative returns on the capital deployed, a common characteristic for biotechnology firms prioritizing asset accumulation and product development over immediate profitability.
估值评估
The trailing twelve-month P/E ratio is N/A given the negative earnings, whereas the forward P/E is listed at 7.07, implying that the market prices the stock based on anticipated future profitability rather than historical performance. The price-to-book ratio stands at 6.17, suggesting that the market values the company at a significant premium over its net asset book value, likely reflecting the intrinsic worth of its intellectual property and pipeline potential. Alternative valuation metrics such as the price-to-sales ratio of 4.94 and the EV/EBITDA of -29.75 provide context, where the negative EV/EBITDA underscores the company's current lack of earnings power while the positive price-to-sales multiple indicates investor confidence in future revenue generation. The 52-week high for the stock is $9.92 and the 52-week low is $4.68, meaning the current trading price sits within this historical range, though the specific current price point is not explicitly defined in the provided data to calculate the exact percentage deviation. The beta value of 0.93 indicates that the stock's price volatility is roughly in line with the broader market, suggesting it does not exhibit excessive sensitivity to general market swings compared to more volatile biotech peers.
Growth & Income
Revenue growth year-over-year is recorded at 73.8%, while earnings growth is N/A due to the company's current lack of profitability, which implies that top-line expansion is the primary driver of stock performance rather than earnings scaling. As a non-dividend payer, Fennec Pharmaceuticals maintains a dividend yield of N/A and a payout ratio of 0.0%, indicating that the company directs all available earnings and cash reserves back into research, development, and commercial expansion rather than distributing income to shareholders. The combination of high revenue growth rates and a zero payout ratio characterizes a classic growth-stage biotechnology profile where capital retention is essential for navigating the long path to product approval and market penetration. The overall growth and income profile is defined by aggressive revenue expansion funded by internal cash reserves and a complete absence of dividend obligations, positioning the asset for potential future earnings realization rather than current income generation.